Abbreviations: HE: Hepatic Encephalopathy; PAMPs: Pathogen associated molecular patterns; TLRs: Toll-like Receptors; NLRs: Nodlike Receptors; LPS: Lipopolysacharide; HCV: Hepatitis C virus; CHB: Chronic Hepatitis B; HBV: Hepatitis B virus; ALD: Alcoholic Liver Disease; BM: Bone Marrow; NAFLD: Nonalcoholic Fatty Liver Disease; NASH: Non-alcoholic steatohepatitis; NO: Nitric Oxide; SIRS: Systemic...

Non-alcoholic fatty liver disease has become one of the most common causes of chronic liver disease that can develop into a more serious form, non-alcoholic steatohepatitis, leading to liver cirrhosis and hepatocellular carcinoma. Although hepatic retinoid stores are progressively lost during the development of liver disease, how this affects steatohepatitis and its related hepatocarcinogenesis...

BACKGROUND & AIMS The modest consumption of alcohol has been reported to decrease the incidence of fatty liver or prevalence of steatohepatitis. In this study, we investigated the effect of light alcohol consumption on liver function and gene expression in patients with non-alcoholic fatty liver disease (NAFLD). METHODS The study group was formed of 178 patients diagnosed with non-alcoholic f...

background: despite the prevalence of non-alcoholic fatty liver disease (nafld) and non-alcoholic steatohepatitis (nash), no treatment has been proven to be effective in these common diseases. although many studies have shown that lifestyle modifications such as increasing physical activities and exercise could be effective in the treatment of these common diseases, the optimal strategy is stil...

Non-alcoholic fatty liver disease (NAFLD) is by far the most common form of chronic liver disease worldwide, affecting adults as well as children. Under the term of NAFLD there is a wide spectrum of diseases ranging from simple steatosis to the non-alcoholic steatohepatitis (NASH), which can progress to cirrhosis and hepatocellular carcinoma (HCC). Several mechanisms have been described to infl...

Tirzepatide, a glucose-dependent insulinotropic polypeptide receptor and glucagon-like peptide-1 agonist has recently been approved by FDA for type 2 diabetes in adults as single dose weekly. Tirzepatide is phase 3 development with obesity or overweight weight-related comorbidity. also under evaluation treatment of non-alcoholic steatohepatitis, heart faialure obstructive sleep apnea.